These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 11455975)

  • 41. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.
    Brisco MJ; Condon J; Hughes E; Neoh SH; Sykes PJ; Seshadri R; Toogood I; Waters K; Tauro G; Ekert H
    Lancet; 1994 Jan; 343(8891):196-200. PubMed ID: 7904666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
    Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
    Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
    Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
    Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.
    Chowdhury S; Bandyopadhyay S; Mandal C; Chandra S; Mandal C
    BMC Cancer; 2008 Feb; 8():40. PubMed ID: 18241334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.
    Yetgin S; Tuncer MA; Cetin M; Gümrük F; Yenicesu I; Tunç B; Oner AF; Toksoy H; Koç A; Aslan D; Ozyürek E; Olcay L; Atahan L; Tunçbilek E; Gürgey A
    Leukemia; 2003 Feb; 17(2):328-33. PubMed ID: 12592331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical significance of sequential monitoring minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
    Wang L; Jiang H; Li H; Shao JB; Lu ZH; Yang JW; Yang WQ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):400-3. PubMed ID: 21781499
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
    Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.
    Paganin M; Fabbri G; Conter V; Barisone E; Polato K; Cazzaniga G; Giraldi E; Fagioli F; Aricò M; Valsecchi MG; Basso G
    J Clin Oncol; 2014 Nov; 32(31):3553-8. PubMed ID: 25287825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
    Eckert C; Hagedorn N; Sramkova L; Mann G; Panzer-Grümayer R; Peters C; Bourquin JP; Klingebiel T; Borkhardt A; Cario G; Alten J; Escherich G; Astrahantseff K; Seeger K; Henze G; von Stackelberg A
    Leukemia; 2015 Aug; 29(8):1648-55. PubMed ID: 25748682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
    Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
    Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
    Kuang S; Gu L; Dong S; Cao Q; Xu C; Huang W; Su XY; Huang QH; Xie JX; Chen SJ; Chen Z
    Cancer Genet Cytogenet; 1996 Jun; 88(2):110-7. PubMed ID: 8640718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
    Baraka A; Sherief LM; Kamal NM; Shorbagy SE
    Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
    Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
    Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Minimal residual disease in acute lymphoblastic leukemia: a new concept of complete remission].
    Bastida Vilá P; Palacio García C; Solsona Riera M; Ortega Aramburu JJ; Sánchez de Toledo Codina J
    An Pediatr (Barc); 2005 Nov; 63(5):390-5. PubMed ID: 16266612
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
    Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
    Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.